deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT01137630

Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp

A Multicenter, Randomised Double Blind, Placebo Controlled Study of Efficacy, Safety and Tolerability of Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp.

Sponsor: Moberg Pharma AB

Conditions Seborrhoeic Dermatitis of the Scalp
Interventions K40a K40b Placebo
Updated 7 times since 2017 Last updated: Jun 3, 2010 Started: Feb 28, 2007 Primary completion: May 31, 2007 Completion: May 31, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Seborrhoeic Dermatitis of the Scalp and is currently completed. Moberg Pharma AB leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jan 2021 · 47 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshotCompleted~Oct 2025 – present · 9 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2_PHASE3

    First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Moberg Pharma AB
Data source: Moberg Pharma AB

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations